Akebia Therapeutics 2025 Q3 Earnings Profit Turnaround Drives 102.7% Net Income Surge

Akebia Therapeutics (AKBA) reported fiscal 2025 Q3 earnings on Nov 10, 2025, delivering a 57% revenue increase and a dramatic net income turnaround. The company surpassed revenue expectations by $2.36 million while transitioning from a $20.04 million net loss to a $540,000 profit. Guidance remains optimistic, with plans to expand Vafseo patient access to 275,000 by year-end and accelerate 2026 growth.

Revenue

. Product revenue, net, , driven by robust performance from Auryxia and Vafseo. License, collaboration, and other revenue contributed $1.98 million, rounding out the total. The company’s flagship product, Auryxia, , , reflecting strong adoption in dialysis care.

Earnings/Net Income

, reversing a $20.04 million loss in the prior-year period. Despite maintaining a stable EPS of $0.00, , underscoring operational efficiency and strategic cost management.

Post-Earnings Price Action Review

Akebia’s stock faced a sharp post-earnings correction, . Month-to-date, , signaling investor skepticism despite the company’s financial turnaround. The mixed market reaction likely stemmed from lingering concerns over operational challenges, including adherence issues and logistical hurdles in scaling Vafseo adoption.

CEO Commentary

John P. Butler, CEO, emphasized progress in establishing Vafseo as a standard of care for dialysis patients, citing a post-hoc analysis at ASN Kidney Week showing improved mortality/hospitalization outcomes. , . .

Guidance

Akebia anticipates concluding the DaVita Vafseo pilot in Q4 2025, . , .

Additional News

Akebia’s strategic focus on dialysis market expansion includes a DaVita pilot to boost patient access and partnerships with US Renal Care. Operational challenges, however, persist in protocol implementation and adherence rates, requiring and inventory adjustments. The company also shelved plans for a Phase 3 trial for non-dialysis patients, narrowing its R&D scope.

Akebia Therapeutics’ Q3 2025 results reflect a pivotal shift toward profitability, driven by Vafseo’s market traction and cost discipline. While revenue growth and cash reserves are robust, operational hurdles in scaling adoption and managing adherence remain critical. The company’s strategic pivot to dialysis-focused growth, bolstered by positive clinical data, .

Additional News

Akebia’s DaVita pilot, initiated to expand Vafseo access, is central to its 2025 growth strategy. The company also announced a partnership with US Renal Care to enhance patient access, though adherence challenges at USRC necessitated protocol adjustments and sales team retraining. Additionally, Akebia confirmed it will not pursue a Phase 3 trial for non-dialysis patients following the FDA Type C meeting, redirecting resources to dialysis-focused initiatives. These moves underscore a strategic focus on high-impact markets while navigating operational complexities.

Financial Health

. However, . , necessitating close monitoring of and market adoption rates.